{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-027930","form_type":"8-K","ticker":"AUPH","cik":"0001600620","company_name":"Aurinia Pharmaceuticals Inc.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.362688+00:00","generated_at":"2026-06-22T09:05:19.986061+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aurinia Q3 net revenue $55.8M (incl. $30M milestone); lowers FY22 product revenue guidance to $100-105M","bullets":["Net loss narrowed to $9.0M ($0.06/sh) from $50.3M loss ($0.39/sh) in Q3 2021.","LUPKYNIS net product revenue $25.5M; 2022 product revenue guidance cut to $100-105M from unstated prior range.","Patients on therapy grew to ~1,354 (up from 1,274 at Q2 2022); PSFs added 374 vs 412 Y/Y.","EC granted marketing authorization for LUPKYNIS in Europe; $30M milestone from Otsuka recognized and received.","Cash at $376.6M (Sep 30) and ~$400M (Oct 31); IPR decision on LUPKYNIS patent expected by July 26, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-027930","json":"https://secwatch.observer/filing/0001628280-22-027930.json","markdown":"https://secwatch.observer/filing/0001628280-22-027930.md","text":"https://secwatch.observer/filing/0001628280-22-027930.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1600620/000162828022027930/0001628280-22-027930-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1600620/000162828022027930/auph-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T09:05:19.986061+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5a9ff388b1f8101f2a857594057d7c3ec81b6ea0","claim":"Aurinia Pharmaceuticals Inc. updated its 2022 guidance (lowered).","evidence_excerpt":"we are adjusting our net revenue guidance to $100-105 million from sales of LUPKYNIS for 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828022027930/0001628280-22-027930-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"2022"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"66a5b38ce8299dff48166ec6c35a0c3d5fb10d08","claim":"Aurinia Pharmaceuticals Inc. reported the three months ended September 30, 2022 results: revenue $55.8 million.","evidence_excerpt":"set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- AURINIA REPORTS THIRD QUARTER AND NINE MONTHS 2022 FINANCIAL AND OPERATIONAL RESULTS Net revenue of $55.8 million for Q3 2022; including $30.0 million milestone from Otsuka related to European Approval of LUPKYNIS ® (voclosporin) Adjusts net product revenue guidance to $100-105 million from","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828022027930/0001628280-22-027930-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended September 30, 2022"},{"label":"Revenue","value":"$55.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"7c2721fbf128c6dcf7755d8f545383804f4f99f0","claim":"Aurinia Pharmaceuticals Inc. updated its 2023 guidance (initiated).","evidence_excerpt":"We are also providing preliminary net revenue guidance from product sales of LUPKYNIS for 2023 in the range of $120-140 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828022027930/0001628280-22-027930-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"2023"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}